Boehringer Ingelheim USA Corporation

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

Open-label, Single Arm Trial of BI 695502 in Patients With Previously Untreated Metastatic Colorectal Cancer

Phase 3

Completed

Conditions: Colorectal Neoplasms

Interventions: Drug: BI 695502
Drug: Avastin

First Posted Date: 2016-05-18

Last Posted Date: 2019-11-21

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 123

Registration Number: NCT02776683

Locations: 🇺🇦
Sumy Regional Oncology Center, Sumy, Ukraine
🇺🇸
The Oncology Institute of Hope and Innovation, Anaheim, California, United States
🇺🇸
Oncology Hematology Care, Cincinnati, Ohio, United States

and more 38 locations

Dose Finding, Efficacy and Safety of BI 655064 in Patients With Active Lupus Nephritis

Phase 2

Completed

Conditions: Lupus Nephritis

Interventions: Drug: BI 655064 dose 1
Drug: BI 655064 dose 2
Drug: BI 655064 dose 3
Drug: Placebo

First Posted Date: 2016-05-12

Last Posted Date: 2021-07-12

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 121

Registration Number: NCT02770170

Locations: 🇺🇸
Feinstein Institute for Medical Research, Manhasset, New York, United States
🇵🇹
Hospital Curry Cabral, EPE, Lisboa, Portugal
🇷🇸
Institute of Rheumatology, Belgrade, Belgrade, Serbia

and more 71 locations

Intravenous BI 836826 in Combination With Ibrutinib in Relapsed/Refractory CLL Patients Who Have Been Pre-treated With at Least One Prior Line of Systemic Therapy, and Who Are Eligible for Treatment With Ibrutinib

Phase 1

Completed

Conditions: Leukemia, Lymphocytic, Chronic, B-Cell

Interventions: Drug: BI 836826
Drug: Ibrutinib

First Posted Date: 2016-05-03

Last Posted Date: 2020-09-29

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 7

Registration Number: NCT02759016

Locations: 🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸
Oregon Health and Sciences University, Portland, Oregon, United States
🇺🇸
City of Hope, Duarte, California, United States

Bioequivalence of a Fixed Dose Combination Tablet of Empagliflozin/Linagliptin Compared With the Free Combination of Empagliflozin Tablet and Linagliptin Tablet in Healthy Male and Female Subjects

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: Empagliflozin
Drug: Linagliptin

First Posted Date: 2016-05-02

Last Posted Date: 2017-11-22

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 56

Registration Number: NCT02758171

Locations: 🇩🇪
Humanpharmakologisches Zentrum Biberach, Biberach, Germany

fMRI in Impulsivity

Completed

Conditions: Impulse Control Disorders
Borderline Personality Disorder

Interventions: Behavioral: Experimental

First Posted Date: 2016-04-28

Last Posted Date: 2018-08-29

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 48

Registration Number: NCT02755181

Locations: 🇺🇸
Virginia Commonwealth University, Richmond, Virginia, United States

Real World Data on Gi(l)Otrif® Dose Adjustment

Completed

Conditions: Carcinoma, Non-Small-Cell Lung

First Posted Date: 2016-04-26

Last Posted Date: 2019-08-08

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 228

Registration Number: NCT02751879

Locations: 🇦🇹
SMZ Baumgartner Hoehe Otto Wagner Spital, Wien, Austria
🇨🇦
BC Cancer Agency - Vancouver, Vancouver, British Columbia, Canada
🇯🇵
Kurashiki Central Hospital, Okayama, Kurashiki, Japan

and more 26 locations

Investigation of the Effect of Nintedanib on the Pharmacokinetics of a Combination of Ethinylestradiol and Levonorgestrel in Patients With Non-small Cell Lung Cancer

Phase 1

Terminated

Conditions: Carcinoma, Non-Small-Cell Lung

Interventions: Drug: Microgynon
Drug: Nintedanib

First Posted Date: 2016-04-26

Last Posted Date: 2019-03-14

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 2

Registration Number: NCT02751385

Locations: 🇩🇪
Klinikum Chemnitz gGmbH, Chemnitz, Germany

Safety and Effect on Central Retinal Thickness of BI 1026706 in Patients With Diabetic Macular Edema

Phase 2

Completed

Conditions: Macular Edema

Interventions: Drug: BI 1026706
Drug: Placebo

First Posted Date: 2016-04-11

Last Posted Date: 2019-03-20

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 105

Registration Number: NCT02732951

Locations: 🇪🇸
Hospital Vall d'Hebron, Barcelona, Spain
🇵🇹
Hospital de Vila Franca de Xira, Vila Franca de Xira, Portugal
🇫🇷
HOP Lariboisière, Paris, France

and more 32 locations

To Investigate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of BI 1467335 Following Multiple Dose Administration Over 28 Days

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: BI 1467335
Drug: Placebo

First Posted Date: 2016-04-11

Last Posted Date: 2021-06-07

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 36

Registration Number: NCT02733627

Locations: 🇩🇪
CRS Clinical Research Services Mannheim GmbH, Mannheim, Germany

Olmutinib (BI 1482694) ADME Study

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: [14C]BI 1482694

First Posted Date: 2016-03-29

Last Posted Date: 2016-07-13

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 8

Registration Number: NCT02722161

Locations: 🇳🇱
1370.7.31001 Boehringer Ingelheim Investigational Site, Zuidlaren, Netherlands

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy